Cargando…

Cancers and Benign Processes on (68) Ga PSMA PET-CT Imaging Other than Prostate Cancer

Background Imaging plays an important role in the evaluation of prostate cancer patients. In recent years, much attention has been focused on gallium 68 prostate-specific membrane antigen positron emission tomography-computed tomography ( (68) Ga PSMA PET-CT) in prostate cancer patients and has bee...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ozcan, Pinar Pelin, Serdengectı, Mustafa, Koc, Zehra Pinar, Balcı, Yüksel, Tek, Mesut, Bozlu, Murat, Akbay, Erdem, Erçolak, Vehbi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Thieme Medical and Scientific Publishers Pvt. Ltd. 2022
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9296244/ https://www.ncbi.nlm.nih.gov/pubmed/35865153 http://dx.doi.org/10.1055/s-0042-1750331

Ejemplares similares

Superscan Appearance of (68)Ga PSMA PET/CT in a Patient with Refractory Prostate Cancer
por: Koç, Zehra Pınar, et al.
Publicado: (2022)

The Relationship between Pathological Features and (18) F-FDG PET/CT that Changed the Surgeon's Decision as Neoadjuvant Therapy in Breast Cancer
por: Edizsoy, Akay, et al.
Publicado: (2022)

[(68)Ga]Ga-PSMA-11: The First FDA-Approved (68)Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer
por: Hennrich, Ute, et al.
Publicado: (2021)

(44)Sc-PSMA-617 for radiotheragnostics in tandem with (177)Lu-PSMA-617—preclinical investigations in comparison with (68)Ga-PSMA-11 and (68)Ga-PSMA-617
por: Umbricht, Christoph A., et al.
Publicado: (2017)

The Role of (18)F-FDG PET/CT in Detecting Ovarian Cancer Recurrence in Patients with Elevated CA-125 Levels
por: Cengiz, Arzu, et al.
Publicado: (2019)

In vitro and in vivo comparative study of a novel (68)Ga-labeled PSMA-targeted inhibitor and (68)Ga-PSMA-11
por: Chen, Huanyu, et al.
Publicado: (2021)

Metabolic Characterization of Anterior Mediastinal Masses by (18)F-FDG PET/CT
por: Koç, Zehra Pınar, et al.
Publicado: (2020)

Detection of unknown primary tumor in patients presented with brain metastasis by F-18 fluorodeoxyglucose positron emission tomography/computed tomography
por: Koç, Zehra Pınar, et al.
Publicado: (2018)

Splenosis Mimicking Lymphoma Relapse Confirmed by (18)F-FDG PET/CT and Tc-99m Nano-colloid Scintigraphy Thirty Years After Splenectomy for Trauma
por: Koç, Zehra Pınar, et al.
Publicado: (2019)

Cyclotron-based production of (68)Ga, [(68)Ga]GaCl(3), and [(68)Ga]Ga-PSMA-11 from a liquid target
por: Rodnick, Melissa E., et al.
Publicado: (2020)

PSMA as a Theranostic Target in Hepatocellular Carcinoma: Immunohistochemistry and (68)Ga‐PSMA‐11 PET Using Cyclotron‐Produced (68)Ga
por: Thompson, Scott M., et al.
Publicado: (2021)

1037 The risk factors for resistant Esherichia coli infections after prostate biopsy under fluoroquinolone prophylaxis
por: Kandemir, Özlem, et al.
Publicado: (2014)

Amyloidosis Associated Kidney Failure with Gross Hypermetabolic Intra-abdominal Mass
por: Koç, Zehra Pınar, et al.
Publicado: (2020)

Musculoskeletal pitfalls in (68)Ga-PSMA PET/CT
por: Pontes, Írline Cordeiro de Macedo, et al.
Publicado: (2023)

Specificity of (68)Ga-PSMA PET/CT for Prostate Cancer - Myths and Reality
por: Sasikumar, Arun
Publicado: (2017)

Multiparametric dynamic whole-body PSMA PET/CT using [(68)Ga]Ga-PSMA-11 and [(18)F]PSMA-1007
por: Dias, André H., et al.
Publicado: (2023)

PSMA Expression in Multinodular Thyroid Neoplasm on Simultaneous Ga-68-PSMA PET/MRI
por: Jena, Amarnath, et al.
Publicado: (2017)

68Ga-PSMA PET/CT in prostate cancer patients – patterns of disease, benign findings and pitfalls
por: Keidar, Zohar, et al.
Publicado: (2018)

Comparison of [(18)F]DCFPyL and [(68)Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer
por: Dietlein, Markus, et al.
Publicado: (2015)

Comparison of [(18)F]PSMA-1007 with [(68)Ga]Ga-PSMA-11 PET/CT in Restaging of Prostate Cancer Patients with PSA Relapse
por: Hoffmann, Manuela A., et al.
Publicado: (2022)

(68)Ga-PSMA-11 PET/CT versus (68)Ga-PSMA-11 PET/MRI for the detection of biochemically recurrent prostate cancer: a systematic review and meta-analysis
por: Huang, Ruizhe, et al.
Publicado: (2023)

F-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Images of Severe Primary Lung Lymphoma
por: Koç, Zehra Pınar, et al.
Publicado: (2020)

Lymphoblastic Involvement of the Bone Marrow as a Cause of Superscan Appearance in (18)F-Fluorodeoxyglucose Positron Emission Tomography/ Computed Tomography
por: Koç, Zehra Pınar, et al.
Publicado: (2020)

Radiation dosimetry of [(68)Ga]PSMA-11 in low-risk prostate cancer patients
por: Sandgren, Kristina, et al.
Publicado: (2019)

(68)Ga-PSMA-PET/CT for the evaluation of liver metastases in patients with prostate cancer
por: Damjanovic, Jonathan, et al.
Publicado: (2019)

Re: The role of (68)Ga-PSMA-PET/CT in radiotherapy planning in prostate cancer
por: Cihan, Yasemin Benderli
Publicado: (2019)

Performance of Ga-68 PSMA PET/CT for diagnosis and grading of local prostate cancer
por: Kwan, Timothy N., et al.
Publicado: (2021)

Voxel-based comparison of [(68)Ga]Ga-RM2-PET/CT and [(68)Ga]Ga-PSMA-11-PET/CT with histopathology for diagnosis of primary prostate cancer
por: Fassbender, Thomas Franz, et al.
Publicado: (2020)

A prospective head-to-head comparison of [(68)Ga]Ga-P16-093 and [(68)Ga]Ga-PSMA-11 PET/CT in patients with primary prostate cancer
por: Wang, Guochang, et al.
Publicado: (2023)

[(68)Ga]Ga-PSMA and [(68)Ga]Ga-RM2 PET/MRI vs. Histopathological Images in Prostate Cancer: A New Workflow for Spatial Co-Registration
por: Ghezzo, Samuele, et al.
Publicado: (2023)

Gallium-68 prostate-specific membrane antigen ([(68)Ga]Ga-PSMA-11) PET for imaging of thyroid cancer: a feasibility study
por: Lawhn-Heath, Courtney, et al.
Publicado: (2020)

Primary Staging of Prostate Cancer Patients with [(18)F]PSMA-1007 PET/CT Compared with [(68)Ga]Ga-PSMA-11 PET/CT
por: Hoffmann, Manuela A., et al.
Publicado: (2022)

Cost-effectiveness of the implementation of [(68)Ga]Ga-PSMA-11 PET/CT at initial prostate cancer staging
por: van der Sar, Esmée C. A., et al.
Publicado: (2022)

What to Trust, PSA or [(68)Ga]Ga-PSMA-11: Learn from Experience
por: Viglialoro, Rita, et al.
Publicado: (2021)

Direct comparison of (99m)Tc-PSMA SPECT/CT and (68)Ga-PSMA PET/CT in patients with prostate cancer
por: Albalooshi, Batool, et al.
Publicado: (2020)

The clinical application of (68)Ga-PSMA PET/CT and regulating mechanism of PSMA expression in patients with brain metastases of lung cancer
por: Pei, Yuchen, et al.
Publicado: (2023)

(68)Ga-PSMA and (68)Ga-DOTA-RM2 PET/MRI in Recurrent Prostate Cancer: Diagnostic Performance and Association with Clinical and Histopathological Data
por: Mapelli, Paola, et al.
Publicado: (2022)

Intraindividual comparison of [(68) Ga]-Ga-PSMA-11 and [(18)F]-F-PSMA-1007 in prostate cancer patients: a retrospective single-center analysis
por: Hoberück, Sebastian, et al.
Publicado: (2021)

Twenty four hour imaging delay improves viability detection by Tl-201 myocardial perfusion scintigraphy
por: Koç, Zehra Pınar, et al.
Publicado: (2013)

PSMA-Positive Follicular Thyroid Carcinoma Incidentally Detected by [(68)Ga]Ga-PSMA-11 PET/CT: Correlation with Immunohistology Confirms Neovascular PSMA-Expression
por: Rosar, Florian, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3paflo26ng6o164ts0cnueg5k1